Literature DB >> 6763622

[Interferon: A greatly simplified immuno enzyme determination with two monoclonal antibodies].

H Gallati.   

Abstract

Human leukocyte interferon (HuIFN-alpha) can be determined by a substantially simplified enzyme-immunological method, based on the solid phase sandwich principle. In a single step, the interferon in the sample or the standard solution (tests and standards are run concomitantly) is bound to a polystyrene bead coated with monoclonal (mouse) anti-interferon, and at the same time it is labelled with a second monoclonal (mouse) interferon antibody, which is coupled to horse radish peroxidase. After this immunological incubation, the non-bound material is removed by washing, and the quantity of peroxidase bound to the bead is measured enzymically. The resulting colour intensity is determined photometrically, and it is directly proportional to the interferon concentration in the sample. The detection limit of the test can be as low as 100 I.U./l interferon, depending on the assay conditions. The variation coefficient within series was 3-6%. Serum samples can be used directly in the test without pretreatment. Depending on the required sensitivity, the incubation may be performed for periods between 30 minutes and 24 hours.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6763622

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  14 in total

1.  The internalization time course of a given lipopolysaccharide chemotype does not correspond to its activation kinetics in monocytes.

Authors:  A Lentschat; V T El-Samalouti; J Schletter; S Kusumoto; L Brade; E T Rietschel; J Gerdes; M Ernst; H Flad; A J Ulmer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells.

Authors:  T Gutsmann; M Müller; S F Carroll; R C MacKenzie; A Wiese; U Seydel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 3.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

4.  Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration.

Authors:  A Supersaxo; W R Hein; H Steffen
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

5.  Effect of in vitro infection of human monocytes with low numbers of Mycobacterium tuberculosis bacteria on monocyte apoptosis.

Authors:  I Dürrbaum-Landmann; J Gercken; H D Flad; M Ernst
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

6.  Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes.

Authors:  J Fleischer; E Soeth; N Reiling; E Grage-Griebenow; H D Flad; M Ernst
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

7.  Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.

Authors:  A Supersaxo; W Hein; H Gallati; H Steffen
Journal:  Pharm Res       Date:  1988-08       Impact factor: 4.200

8.  Investigation into the interaction of the bacterial protease OmpT with outer membrane lipids and biological activity of OmpT:lipopolysaccharide complexes.

Authors:  Klaus Brandenburg; Patrick Garidel; Andra B Schromm; Jörg Andrä; Arjen Kramer; Maarten Egmond; Andre Wiese
Journal:  Eur Biophys J       Date:  2004-07-06       Impact factor: 1.733

9.  Tumor necrosis factor and interferon as prognostic markers in human immunodeficiency virus (HIV) infection.

Authors:  G Hess; S Rossol; R Rossol; K H Meyer zum Büschenfelde
Journal:  Infection       Date:  1991       Impact factor: 3.553

10.  Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

Authors:  S Rossol; G Gianni; R Rossol-Voth; H Gallati; W E Müller; K H Meyer zum Büschenfelde
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.